February 2010: Pharmawire Interview

“TauRx to initiate two global Phase III Alzheimer's trials in 4Q 2010, in advanced stage of CRO selection and active US investigator discussions” –Wischik describes the Company’s plans to take forward late stage clinical development of its second generation Tau Aggregation Inhibitor.